CVS Health (CVS) investor relations material

Business momentum and operational progress

• Significant momentum across health plan, pharmacy, and healthcare delivery segments, with disciplined execution driving recovery toward target margins, especially in Aetna and pharmacy businesses.

• Investments in technology and talent are yielding mid-single digit growth in pharmacy, reversing previous declines.

• Oak Street's profitability challenges have been addressed, with steady improvement and expectations for positive contributions in coming years.

• Enhanced capital position allows for increased cash generation and disciplined capital deployment, including potential share repurchases and bolt-on acquisitions.

• Strong leadership and new executive team at Aetna have improved fundamentals, innovation, and competitive positioning.

Market trends, cost management, and innovation

• Medical cost trends remain elevated, prompting over 2,000 initiatives to manage costs and drive innovation, including partnerships with providers and digital navigation tools.

• Medicare Advantage (MA) business is focused on margin recovery, with improved geographic and product mix, and leading star scores supporting future stability.

• Medicaid business is stable and aligned with expectations, with strong state partnerships and effective rate advocacy.

• Ongoing policy changes, such as Medicaid work requirements, are being managed through close collaboration with states and proactive communication.

• Product innovation includes digital tools, Smart Compare, and clinical programs targeting high-cost areas like autism, aiming for better outcomes and lower costs.

Pharmacy, 340B, and selling season dynamics

• Pharmacy and consumer wellness segment is experiencing durable growth, driven by the CostVantage model and investments in technology and workforce.

• 340B program headwinds are being absorbed, with expectations for stabilization by 2027 and prudent guidance provided for future performance floors.

• Selling season is less robust than prior years, with retention rates normalizing to industry averages as contract discipline increases.

• Profitability focus includes ensuring fair margins on every script, especially with high-profile drug categories like GLP-1s.

• Improvements in cost of goods sold are shared with payer partners, benefiting both in-house and external PBM relationships.